SCHEMBL25835895

SCHEMBL25835895

CC(C)(C)OC(=O)NCc1cnc(-c2ccc(F)cc2)cc1-c1ccn(CC(N)=O)n1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 2/20 0.43
NTRK1 P04629 1/20 0.37
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36
SCN9A Q15858 5/20 0.36
AR P10275 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
SCN4A P35499 1/20 0.33
HTR2C P28335 3/20 0.33
MCHR1 Q99705 3/20 0.33
ATR Q13535 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
ACACB O00763 1/20 0.33
ACACA Q13085 1/20 0.33
CACNA1G O43497 1/20 0.32
CACNA1H O95180 1/20 0.32
AAK1 Q2M2I8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30510167 1.00 GRM2 (0.43) GRM2NTRK1ALOX5APFEN1SCN9A
SCHEMBL25837946 0.87 NTRK1 (0.46) GRM2NTRK1ALOX5APFEN1SCN9A
SCHEMBL30509985 0.87 NTRK1 (0.46) GRM2NTRK1ALOX5APFEN1SCN9A
SCHEMBL30510098 0.87 AR (0.40) GRM2NTRK1ALOX5APFEN1AR
SCHEMBL25835853 0.87 AR (0.40) GRM2NTRK1ALOX5APFEN1AR
SCHEMBL25257184 0.86 HDAC1 (0.35) GRM2SCN9AGRIN1GRIN2BSCN4A
SCHEMBL25253758 0.83 KDR (0.35) GRM2SCN9AGRIN1GRIN2BSCN4A
SCHEMBL30510094 0.82 MRGPRX4 (0.39) GRM2NTRK1HTR2CMCHR1ACACB
SCHEMBL25256203 0.82 MRGPRX4 (0.39) GRM2NTRK1HTR2CMCHR1ACACB
SCHEMBL26193320 0.82 CDK9 (0.36) GRM2NTRK1ALOX5APFEN1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4452253-A2 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD The Katholieke Universiteit Leuven (BE) 2024-10-30 EP disclosed
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 US disclosed
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 US disclosed
WO-2023122780-A9 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
WO-2023122780-A9 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD KU LEUVEN R&D (BE) 2023-09-07 US disclosed
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD KU LEUVEN R&D (BE) 2023-09-07 US disclosed
WO-2023122780-A2 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-06-29 WO disclosed
WO-2023122780-A2 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 GRM2 4239/4885NTRK1 3857/4885ALOX5AP 3911/4885
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 GRM2 4239/4885NTRK1 3857/4885ALOX5AP 3911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.